Cannabis and Chemotherapy Side Effects
Evidence for cannabis in managing chemotherapy side effects, with honest assessment of risks and gaps.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Synthetic THC pills work for nausea when standard drugs fail—that's real and FDA-approved. For pain, neuropathy, and appetite, the evidence is modest at best. Cannabis absolutely does not cure cancer; patients who skip chemo for cannabis oil are taking a life-threatening gamble on anecdotes and wishful thinking. The risks—drug interactions, immunotherapy interference, infection during neutropenia—are specific and serious. Use it only with your oncologist's knowledge.
Not Medical Advice
This article is not medical advice. It summarizes published evidence as of October 2026. Cancer treatment is individualized, cannabis can interact with chemotherapy drugs, and what is appropriate for one patient may be harmful for another. Discuss any cannabis use—including CBD and THC products—with your oncologist and pharmacist before starting. Tell them honestly what you are taking, in what form, and how often. They have seen it before and would rather know.
Plain-Language Summary
Chemotherapy causes a cluster of difficult side effects: nausea and vomiting, pain, fatigue, appetite loss, nerve damage (neuropathy) in the hands and feet, anxiety, and insomnia. Both pharmaceutical cannabinoids (dronabinol, nabilone) and whole-plant cannabis have been studied for some of these.
The short version:
- Nausea and vomiting: Synthetic THC pills (dronabinol, nabilone) work and are FDA-approved for this when standard anti-nausea drugs fail. Strong evidence[1][2][3]
- Pain: Modest benefit at best. Cannabinoids reduce pain scores slightly, but placebo does too. Weak / limited[4]
- Nerve damage from chemo (CIPN): Cannabis has shown some benefit in trials for non-cancer nerve pain. Chemo-induced neuropathy specifically: few direct studies. Weak / limited[5]
- Appetite: Better evidence in HIV wasting than in cancer muscle loss. Weak / limited[6]
- Killing cancer: Lab and animal studies show cannabinoids can slow tumor cells in dishes and mice. Human evidence that cannabis treats cancer does not exist at any rigorous level and should not change treatment decisions. No data[7]
Nobody should stop chemotherapy or radiation in favor of cannabis. That is the single most important sentence in this article.
What Probably Works
Synthetic THC for chemotherapy-induced nausea and vomiting (CINV).
Dronabinol (Marinol) and nabilone (Cesamet) are FDA-approved oral cannabinoids for CINV that has not responded to conventional anti-nausea drugs. Strong evidence[1][2] Meta-analyses of controlled trials from the 1980s onward show cannabinoids outperform placebo for nausea control. Strong evidence[2][3]
Important caveats: most older trials predate modern anti-nausea drugs like ondansetron and the NK1 antagonists (aprepitant), which are now first-line. Synthetic cannabinoids today are generally a second- or third-line option when standard regimens fail or cause intolerable side effects. Strong evidence[1] Whether smoked or vaporized whole-plant cannabis is equivalent to oral synthetic THC for CINV is plausible biologically but not rigorously established—the controlled trial data is overwhelmingly on pill formulations. Weak / limited[1]
The National Academies of Sciences, Engineering, and Medicine concluded in 2017 that there is conclusive or substantial evidence that oral cannabinoids are effective for CINV. Strong evidence[3]
What Might Work
Cancer-related pain. Nabiximols (Sativex, a 1:1 THC:CBD oral spray) has been tested as add-on therapy for opioid-resistant cancer pain. Results are mixed: some Phase II trials showed benefit, but larger Phase III trials mostly failed to reach their primary endpoints. Weak / limited[4] The honest assessment is a small effect in some patients and no effect in most.
Sleep and anxiety during treatment. Patients frequently report improvement with THC and CBD, and these cannabinoids have biological mechanisms relevant to sleep and anxiety. However, high-quality randomized trials specifically in cancer patients are sparse. Evidence rests on case reports and small open-label studies. Anecdote
Chemotherapy-induced peripheral neuropathy (CIPN). Cannabis has shown modest benefit in trials of non-cancer neuropathic pain (HIV neuropathy, diabetic neuropathy). Weak / limited[5] Direct randomized trials in CIPN are few and small. Extrapolation from other neuropathic pain syndromes is biologically reasonable but not proven. Weak / limited
Appetite stimulation and cachexia (muscle wasting). Dronabinol increases appetite in HIV-related wasting. Strong evidence In cancer cachexia, results are less impressive. One major multicenter randomized trial found cannabis extract no better than placebo for appetite, weight gain, or quality of life in advanced cancer patients. Weak / limited[6]
What Doesn't Work, or Has Weak Evidence
Cannabis as a cancer treatment. This is the most important section.
Preclinical research—cannabinoids tested in cancer cells grown in dishes and in mice with implanted tumors—has shown that some cannabinoids can slow growth or trigger cell death in certain cancer cell lines. Weak / limited[7] This is interesting basic science. It is not evidence that cannabis cures, shrinks, or stops cancer in humans. No randomized controlled trial has demonstrated that cannabis shrinks tumors or extends survival in any cancer patient. No data
Patients who replace chemotherapy or radiation with cannabis oil ('Rick Simpson Oil,' RSO) are taking a real risk based on social media claims and unreplicated case reports. Published case series have documented patients with curable cancers—including early-stage testicular cancer and lymphoma—who declined standard treatment in favor of cannabis oil and died of cancer progression. Weak / limited[8]
Strain claims for specific cancers. No evidence exists. The "indica vs. sativa" framework does not map to clinical outcomes. Claims that a particular cultivar treats a particular tumor are marketing folklore, not medicine. No data
CBD-only products for chemotherapy nausea. The antiemetic evidence in controlled trials is for THC. CBD alone has not been shown to control CINV. No data
What We Don't Know
- Optimal dose, frequency, THC:CBD ratio, and route (edible vs. vaporized vs. sublingual spray) for any oncology indication.
- Whether vaporized flower delivers antiemetic benefit equivalent to oral pharmaceutical THC.
- Long-term safety profile of daily cannabis use across multiple cycles of chemotherapy.
- Whether cannabis affects the efficacy of chemotherapy drugs or immunotherapy (some retrospective data is concerning; see Risks).
- Whether CBD specifically reduces chemotherapy-induced neuropathy (most evidence is for THC or whole-plant products).
- Pediatric oncology use beyond severe refractory epilepsy.
- Mechanisms by which cannabis might impair immunotherapy response.
Comparison with Standard Treatments
For CINV, modern standard care is a combination of a 5-HT3 antagonist (ondansetron, palonosetron), a corticosteroid (dexamethasone), and for highly emetogenic chemotherapy regimens, an NK1 antagonist (aprepitant) and sometimes olanzapine. These work well for most patients. Cannabinoids are added when this combination fails or causes side effects. [1]
For cancer pain, opioids remain first-line for moderate-to-severe pain, with gabapentinoids and other adjuvants for neuropathic components. Cannabis is, at best, an adjunct that may allow modest opioid sparing in some patients—not a replacement. [4]
For appetite stimulation and cachexia, megestrol acetate and corticosteroids have somewhat more evidence in cancer than cannabinoids, though all have limited efficacy and meaningful side effects.
The practical role of cannabis in oncology supportive care is: a reasonable add-on for patients whose symptoms are not controlled by standard treatment, used only with the oncology team's knowledge and oversight.
Risks and Interactions
Drug interactions. CBD (and to a lesser extent THC) inhibits cytochrome P450 enzymes—particularly CYP3A4 and CYP2C19—that metabolize many chemotherapy drugs, including tamoxifen, cyclophosphamide, vincristine, and several tyrosine kinase inhibitors. Weak / limited[9] This can raise or lower drug levels unpredictably. Tell your oncology pharmacist and pharmacogenomics team what cannabis product you are using, in what dose, and how often. See Cannabis and Polypharmacy Risks for more detail.
Immunotherapy. A retrospective study suggested cannabis use was associated with reduced response rates to nivolumab (a PD-1 checkpoint inhibitor) in patients with advanced cancer. Weak / limited[10] This is preliminary data and does not prove causation, but it is reason enough for patients on checkpoint inhibitors to discuss cannabis with their oncologist before use.
Infection risk. Patients on active chemotherapy are often immunocompromised. Smoked cannabis can carry fungal contaminants (Aspergillus species) and bacteria. Inhalation routes carry the highest risk; tested edibles and pharmaceutical formulations (pills, sprays) are safer choices during periods of neutropenia or severe immunosuppression.
Cardiovascular effects. THC increases heart rate and can lower blood pressure—relevant for patients on cardiotoxic chemotherapy (anthracyclines, some tyrosine kinase inhibitors, checkpoint inhibitors).
Psychiatric effects. THC can trigger anxiety, paranoia, and in genetically vulnerable individuals, psychotic symptoms. See THC Dose and Anxiety and Biphasic Effects of THC on Anxiety. Patients coping with a cancer diagnosis may have lower tolerance for these effects and higher vulnerability to psychiatric adverse events.
Fall risk. Especially in older adults or those on opioids and benzodiazepines. See Cannabis Use in Older Adults.
None of this means cannabis is forbidden during chemotherapy. It means cannabis is a real drug with real pharmacology, and it deserves to be managed accordingly—with the full knowledge and collaboration of the cancer care team.
Sources
- Peer-reviewed Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database of Systematic Reviews. 2015;11:CD009464.
- Peer-reviewed Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
- Peer-reviewed Lichtman AH, Lux EA, McQuade R, et al. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. Journal of Pain and Symptom Management. 2018;55(2):179–188.e1.
- Peer-reviewed Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2018;3:CD012182.
- Peer-reviewed Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of Clinical Oncology. 2006;24(21):3394–3400.
- Peer-reviewed Velasco G, Sánchez C, Guzmán M. Anticancer mechanisms of cannabinoids. Current Oncology. 2016;23(S1):S23–S32.
- Peer-reviewed Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal of the National Cancer Institute. 2018;110(1):121–124.
- Peer-reviewed Alsherbiny MA, Li CG. Medicinal Cannabis—Potential Drug Interactions. Medicines. 2019;6(1):3.
- Peer-reviewed Taha T, Meiri D, Talhamy S, Wollner M, Peer A, Bar-Sela G. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. The Oncologist. 2019;24(4):549–554.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Cancer — Evidence-based overview of cannabis in cancer supportive care, symptom management, and doc...
- Cannabis and Chemotherapy-Induced Nausea and Vomiting — Synthetic THC drugs treat refractory CINV, but modern antiemetics remain first-line. Smoke...
- Cannabis and Concussion Recovery — Preclinical biology is interesting; human evidence for concussion recovery is essentially...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis Use in Older Adults — What the evidence shows about cannabis benefits and risks for people over 65.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...